Nanobodies targeting programmed cell death protein ligand-1 (PD-L1) and cytotoxic T lymphocyte-associated protein-4, when combined with a single injection of the engineered lysis system, demonstrated an improved therapeutic response, including activation of tumor-infiltrating T cells and rapid tumor regression, compared to similar clinically relevant antibodies alone [94]. This evidence concerns the gene CD274 and neoplasm.